The FDA greenlit Tregzi, Orca Bio's personalized T-cell therapy for blood cancer patients undergoing stem cell transplants — a first-of-its-kind treatment designed to dismantle the brutal trade-off between a potential cure and life-altering graft-versus-host disease. "Historically, the choice for a stem cell transplant carried risks and complications that patients had to accept," CEO Nate Fernhoff told STAT. "With Tregzi's approval, we hope to show that we can break that trade...